Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia
The most frequent subtype of acute myeloid leukemia (AML) is defined by mutations in the nucleophosmin 1 (NPM1) gene. Mutated NPM1 (ΔNPM1) is an attractive target for immunotherapy, since it is an essential driver gene and 4 bp frameshift insertions occur in the same hotspot in 30%–35% of AMLs, resulting in a C-terminal alternative reading frame of 11 aa. By searching the HLA class I ligandome of primary AMLs, we identified multiple ΔNPM1-derived peptides. For one of these peptides, HLA-A*02:01–binding CLAVEEVSL, we searched for specific T cells in healthy individuals using peptide-HLA tetramers. Tetramer-positive CD8+ T cells were isolated and analyzed for reactivity against primary AMLs. From one clone with superior antitumor reactivity, we isolated the T cell receptor (TCR) and demonstrated specific recognition and lysis of HLA-A*02:01–positive ΔNPM1 AML after retroviral transfer to CD8+ and CD4+ T cells. Antitumor efficacy of TCR-transduced T cells was confirmed in immunodeficient mice engrafted with a human AML cell line expressing ΔNPM1. In conclusion, the data show that ΔNPM1-derived peptides are presented on AML and that CLAVEEVSL is a neoantigen that can be efficiently targeted on AML by ΔNPM1 TCR gene transfer. Immunotherapy targeting ΔNPM1 may therefore contribute to treatment of AML.
|Persistent URL||dx.doi.org/10.1172/jci97482, hdl.handle.net/1765/114988|
|Journal||Journal of Clinical Investigation|
van der Lee, D.I., Reijmers, R.M., Honders, M. W., Hagedoorn, R.S., de Jong, R.C.M., Kester, M.G.D, … Griffioen, M. (2019). Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia. Journal of Clinical Investigation, 129(2), 774–785. doi:10.1172/jci97482